According to a report published by Market Research Future (MRFR), the global atopic dermatitis market has been assessed to witness remarkable growth at an 8.2% CAGR over the forecast period of 2017 to 2023.
The global atopic dermatitis market has been segmented on the basis of type, application, end-user, and region.
Based on type, it is segmented into calcitonin, erythropoietin, hormone, interferon, monoclonal antibodies, and others.
Based on application, the atopic dermatitis market is segmented into blood disorders, cancer, chronic diseases, infectious diseases, and others.
Based on end-users, it is segmented into clinics, hospitals, and research centers.
The global atopic dermatitis market is primarily driven by the growing prevalence of atopic dermatitis, the increasing incidence of food allergies, and the rising level of air pollution.
Atopic dermatitis is one of the most common but severe types of eczema, which causes a red, itchy rash usually on the arms, cheeks, and legs. It makes the patient’s skin and immune system extremely sensitive and reactive to the smallest allergens or irritants.
The key players in the global atopic dermatitis market are Anacor Pharmaceuticals Inc. (U.S.), Bristol-Myers Squibb (U.S.), Meda Pharmaceuticals (U.S.), Pfizer Inc. (U.S.), Regeneron Pharmaceuticals, Inc. (U.S.), Valeant Pharmaceuticals International, Inc (Canada), Allergan Plc. (Republic of Ireland), Astellas Pharma Inc. (Japan), Galderma S.A. (Switzerland), Novartis International AG (Switzerland), Sanofi S.A. (France), and others.